Results from a recent German study suggest that a combination of Revlimid, Treanda and prednisone is active and well tolerated in patients with relapsed or refractory multiple myeloma.

Findings from the Phase 1 trial were presented at the 17^th Congress of the European Hematology Association (EHA) in Amsterdam last month.

A previous Phase 1 study showed that Treanda (bendamustine), in combination with Revlimid (lenalidomide) and dexamethasone (Decadron), is well tolerated and highly active in patients with relapsed or refractory myeloma (see related Beacon news).

Treanda, which already is …

In a recent study, an international research team reported several new genetic mutations that may be involved in multiple myeloma. Additionally, the researchers identified genetic changes associated with disease progression.

Dr. Niccolo Bolli from the University of Cambridge in the United Kingdom presented the findings last month at the 17th Congress of the European Hematology Association (EHA).

In multiple myeloma, as with all cancers, cells develop genetic abnormalities known as “mutations.” These mutations can lead to uncontrolled growth and survival of the cancer cells.  In multiple myeloma, mutations typically result in the …

Follow-up results from a long-term study conducted in Italy indicate that quality of response may be the most significant predictor of long-term survival in newly diagnosed multiple myeloma patients receiving a stem cell transplant.

The results also showed that hemoglobin levels and platelet counts at diagnosis were independent factors predicting for long-term survival.

“[This study] confirms the importance of achieving high-quality responses not only as a surrogate marker of progression-free survival and overall survival but also for long-term overall survival,” said Dr. Elena Zamagni, one of study’s investigators from Seragnoli Institute of …

Multiple myeloma physicians and researchers are gathering at the 17^th Congress of the European Hematology Association (EHA) to share the latest findings in the field. The meeting started today in Amsterdam and will run through Sunday, June 17.

The Myeloma Beacon will report on the most important myeloma-related findings from the meeting over the next couple of weeks.

The research presented at the meeting will cover all areas of hematology, which is the study of blood, blood-forming organs, and blood-related diseases, including multiple myeloma.

Today physicians and researchers have the opportunity to …